Catalytic transfer hydrogenation and anticancer activity of arene–ruthenium compounds incorporating bi-dentate precursors

• Published in: Dalton transactions : an international journal of inorganic chemistry Vol. 44; no. 36; pp. 16107 - 16118
• Main Authors: Chang, Yu-Hsiang, Leu, Wohn-Jenn, Datta, Amitabha, Hsiao, Hung-Chang, Lin, Chia-Her, Guh, Jih-Hwa, Huang, Jui-Hsien
• Format: Journal Article
• Language: English
• Published: England 28.09.2015
• Subjects: Anticancer properties; Catalysis; Catalysts; Diffraction; Drugs; Hydrogenation; Ligands; Ruthenium compounds
• ISSN: 1477-9226; 1477-9234; 1477-9234
• DOI: 10.1039/C5DT01310K

Ruthenium based organometallic compounds are presently a subject of great attention as anticancer drugs and appear to work reasonably well on tumor cells. We develop a series of mononuclear arene–ruthenium compounds incorporating N,O and N,N bidentate ligands, and their activity as anticancer drugs against human hormone-refractory metastatic prostate cancer (HRMPCs) cell lines are investigated. The ruthenium compounds also act as effective catalysts in the transfer hydrogenation of the –CO– → –CH(OH)– system. Three types of ligands, namely, sodium glutamate, C 4 H 3 NH(2-CH 2 NH t Bu), and C 4 H 3 NH(2-CHNR) are separately coupled with [(η 6 -cymene)RuCl 2 ] 2 ( 1 ) (cymene = 4-isopropyltoluene) to synthesize five Ru-derivatives: [(η 6 -cymene)RuCl(κ 2 - N , O -OOCCHNH 2 CH 2 CH 2 COOH)] ( 2 ), {(η 6 -cymene)RuCl[C 4 H 3 N(2-CH 2 NH t Bu)]} ( 3 ), {(η 6 -cymene)RuCl[C 4 H 3 N(2-CHNCH 2 Ph)]} ( 4 ), {(η 6 -cymene)RuCl{C 4 H 3 N[2-CHNCH 2 (C 4 H 7 O)]}} ( 5 ) and {(η 6 -cymene)RuCl[C 4 H 3 N(2-CH n BuNHCH 2 (C 4 H 7 O))]} ( 7 ). To the best of our knowledge, the aforementioned Ru compounds are not only characterized by 1 H and 13 C NMR spectroscopy, but for the first time their structures have been established by single crystal X-ray diffractometry. Compound 4 influences a concentration-dependent apoptosis in PC-3 cells and initiates the conversion rate in transfer hydrogenation.